{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:28:30Z","timestamp":1791217710019,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002010.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T00:00:00Z","timestamp":1394668800000}}],"reference-count":84,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002010.pub4","type":"journal-article","created":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T00:05:57Z","timestamp":1394755557000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bisphosphonates for osteoporosis in people with cystic fibrosis"],"prefix":"10.1002","author":[{"given":"Louise S","family":"Conwell","sequence":"first","affiliation":[{"name":"Lady Cilento Children's Hospital; Endocrinology and Diabetes; Stanley St South Brisbane Brisbane Queensland Australia 4101"},{"name":"University of Queensland; School of Medicine and Queensland Children's Medical Research Institute; 300 Herston Road Herston Queensland Australia 4006"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne B","family":"Chang","sequence":"additional","affiliation":[{"name":"Menzies School of Health Research, Charles Darwin University; Child Health Division; PO Box 41096 Darwin Northern Territories Australia 0811"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,13]]},"reference":[{"key":"10.1002\/14651858.CD002010.pub4-BIB0001|cit1","first-page":"365","article-title":"Efficacy of pamidronate for osteoporosis in cystic fibrosis patients following lung transplantation [abstract]","volume":"Suppl 17","author":"Aris","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"3 part 1","key":"10.1002\/14651858.CD002010.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1164\/ajrccm.162.3.2002051","article-title":"Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation","volume":"162","author":"Aris","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0003|cit3","first-page":"364","article-title":"Effect of pamidronate on bone biomarkers in post-transplant osteoporotic cystic fibrosis patients [abstract]","volume":"Suppl 17","author":"Aris","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0004|cit4","first-page":"351","article-title":"Efficacy of alendronate in CF adults with low bone density","volume":"S25","author":"Aris","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.200307-1049OC","article-title":"Efficacy of alendronate in adults with cystic fibrosis with low bone density","volume":"169","author":"Aris","year":"2004","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"S28","key":"10.1002\/14651858.CD002010.pub4-BIB0006|cit6","first-page":"353","article-title":"Zoledronate therapy for decreased bone density in adults with cystic fibrosis [abstract]","volume":"40","author":"Boyle","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Chapman I Greville H Ebeling PR King SJ Kotsimbos T Nugent P Intravenous zoledronate improves bone density in adults with cystic fibrosis Clinical Endocrinology 2009 838 846","DOI":"10.1111\/j.1365-2265.2008.03434.x"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/thorax.56.4.314","article-title":"Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis","volume":"56","author":"Haworth","year":"2001","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0009|cit9","first-page":"295","article-title":"Pamidronate increases axial bone density in cystic fibrosis patients [abstract]","volume":"Suppl 19","author":"Haworth","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002010.pub4-BIB0010|cit10","first-page":"A67","article-title":"Intravenous pamidronate increases axial bone density in cystic fibrosis adults [abstract]","volume":"54","author":"Haworth","year":"1999","journal-title":"Thorax"},{"issue":"9167","key":"10.1002\/14651858.CD002010.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(05)75096-0","article-title":"Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis [letter]","volume":"353","author":"Haworth","year":"1999","journal-title":"Lancet"},{"issue":"9142","key":"10.1002\/14651858.CD002010.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(05)79826-3","article-title":"Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis [letter]","volume":"352","author":"Haworth","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD002010.pub4-BIB0013|cit13","first-page":"423","article-title":"Two-year multicenter, randomised, double-blind, placebo-controlled trial assessing the effect of weekly Risedronate on bone mineral density in adults with CF [abstract]","volume":"45","author":"Haworth","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub4-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jcf.2011.07.007","article-title":"Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis","volume":"10","author":"Haworth","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002010.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(10)60328-1","article-title":"Multicentre randomised double blind placebo controlled trial assessing the effect of weekly risedronate on bone mineral density in adults with cystic fibrosis [abstract]","volume":"9","author":"Haworth","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1378\/chest.08-0608","article-title":"Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial)","volume":"134","author":"Papaioannou","year":"2008","journal-title":"Chest"},{"issue":"8","key":"10.1002\/14651858.CD002010.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/thx.2002.002568","article-title":"Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study","volume":"59","author":"Conway","year":"2004","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1515\/JPEM.2005.18.6.589","article-title":"Growth hormone improves bone mineral content in children with cystic fibrosis","volume":"18","author":"Hardin","year":"2005","journal-title":"Journal of paediatric endocrinology & metabolism: JPEM"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0019|cit19","unstructured":"Alicandro G Bisogno A Battezzati A Bianchi ML Corti F Colombo C Recurrent pulmonary exacerbations are associated with low fat free mass and low bone mineral density in young adults with cystic fibrosis Journal of Cystic Fibrosis S1569 993"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0020|cit20","unstructured":"Ambroszkiewicz J Sands D Gajewska J Chelchowska M Laskowska-Klita T Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis Advances in Medical Sciences 1 6"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1378\/chest.109.5.1176","article-title":"Severe osteoporosis before and after lung transplantation","volume":"109","author":"Aris","year":"1996","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-128-3-199802010-00004","article-title":"Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis","volume":"128","author":"Aris","year":"1998","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1210\/jc.2004-1629","article-title":"Consensus Statement: Guide to Bone Health and Disease in Cystic Fibrosis","volume":"90","author":"Aris","year":"2005","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1359\/JBMR.051106","article-title":"BMD and body composition in children and young patients affected by cystic fibrosis","volume":"21","author":"Bianchi","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9041","key":"10.1002\/14651858.CD002010.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone","volume":"16","author":"Boutsen","year":"2001","journal-title":"Journal of Bone Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.mcp.0000245708.59138.a4","article-title":"Update on maintaining bone health in cystic fibrosis","volume":"12","author":"Boyle","year":"2006","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/thorax.2003.006726","article-title":"Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study","volume":"59","author":"Buntain","year":"2004","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/thx.2005.046516","article-title":"Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis","volume":"61","author":"Buntain","year":"2006","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub4-BIB0030|cit30","first-page":"18","article-title":"Prevalence of bone mineral disease among adolescents with cystic fibrosis","volume":"84","author":"Caldeira","year":"2008","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0031|cit31","unstructured":"Cates C Visual Rx. Online NNT Calculator 2003"},{"issue":"10","key":"10.1002\/14651858.CD002010.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4065\/77.10.1031","article-title":"Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?","volume":"77","author":"Cryer","year":"2002","journal-title":"Mayo Clinic proceedings. Mayo Clinic"},{"issue":"12","key":"10.1002\/14651858.CD002010.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group","volume":"332","author":"Cummings","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0034|cit34","volume-title":"Patient Registry 2012 Annual Report","author":"Cystic Fibrosis Foundation","year":"2013"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0035|cit35","article-title":"Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group","volume-title":"Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group","author":"Cystic Fibrosis","year":"February 2007"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bone.2004.05.021","article-title":"Severe osteopenia in CFTR-null mice","volume":"35","author":"Dif","year":"2004","journal-title":"Bone"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jped.2013.03.008","article-title":"Bone mineral density, pulmonary function, chronological age, and age at diagnosis in children and adolescents with cystic fibrosis","volume":"89","author":"Donadio","year":"2013","journal-title":"Jornal de Pediatria"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/art.1780390307","article-title":"Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial","volume":"39","author":"Eggelmeijer","year":"1996","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD002010.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01625440","article-title":"Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis","volume":"1","author":"Fromm","year":"1991","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2013.01.032","article-title":"Biomedical applications of bisphosphonates","volume":"167","author":"Giger","year":"2013","journal-title":"Journal of Controlled Release: official journal of the Controlled Release Society"},{"issue":"14","key":"10.1002\/14651858.CD002010.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0042|cit42","first-page":"926045","article-title":"A roadmap to the brittle bones of cystic fibrosis","volume":"2011","author":"Gore","year":"2010","journal-title":"Journal of Osteoporosis"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00198-003-1388-1","article-title":"Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: comparison with healthy controls","volume":"14","author":"Greer","year":"2003","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"218691","DOI":"10.1155\/2010\/218691","article-title":"Vitamin D deficiency in cystic fibrosis","volume":"2010","author":"Hall","year":"2010","journal-title":"International Journal of Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/MCP.0b013e32833e2e94","article-title":"Impact of cystic fibrosis on bone health","volume":"16","author":"Haworth","year":"2010","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1378\/chest.11-0132","article-title":"Pain is a common problem affecting clinical outcomes in adults with cystic fibrosis","volume":"140","author":"Hayes","year":"2011","journal-title":"Chest"},{"issue":"7414","key":"10.1002\/14651858.CD002010.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0048|cit48","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0049|cit49","unstructured":"International Society for Clinical Densitometry 2013 ISCD Official Positions [Updated August 2013] www.iscd.org"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled clinical trials"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jbspin.2010.11.015","article-title":"Bone disease in cystic fibrosis: What's new?","volume":"78","author":"Javier","year":"2011","journal-title":"Joint, Bone, Spine: Revue du Rhumatisme"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0052|cit52","volume-title":"Osteoporosis","author":"Kanis","year":"1994"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2013.02.008","article-title":"Update on cystic fibrosis-related diabetes","volume":"12","author":"Kelly","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.ajpath.2012.01.039","article-title":"The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation","volume":"180","author":"Henaff","year":"2012","journal-title":"The American Journal of Pathology"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcf.2009.11.005","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone","volume":"9","author":"Heron","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jbspin.2011.05.009","article-title":"Bone loss in adults with cystic fibrosis: prevalence, associated factors, and usefulness of biological markers","volume":"79","author":"Legroux-Gerot","year":"2012","journal-title":"Joint, bone, spine : revue du rhumatisme"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","article-title":"The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis","volume":"86","author":"Paccou","year":"2010","journal-title":"Calcified Tissue International"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/MCP.0b013e3283659e35","article-title":"Cystic fibrosis-related bone disease","volume":"19","author":"Paccou","year":"2013","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11914-008-0006-8","article-title":"Osteonecrosis of the jaws and bisphosphonates","volume":"6","author":"Pendrys","year":"2008","journal-title":"Current osteoporosis reports"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub4-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005088.pub2","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Phillipi","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.prrv.2012.03.005","article-title":"Cystic fibrosis: what to expect now in the early adult years","volume":"13","author":"Quon","year":"2012","journal-title":"Paediatric Respiratory Reviews"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0062|cit62","unstructured":"The Cochrane Collaboration Review Manager (RevMan) 2003"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0063|cit63","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"4922","key":"10.1002\/14651858.CD002010.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characteristics of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCP.0b013e32834b7f51","article-title":"Liver disease in cystic fibrosis","volume":"17","author":"Rowland","year":"2011","journal-title":"Current Opinion in Pulmonary Medicine"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates from bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Annals New York Academy of Sciences"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1002\/14651858.CD002010.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ocl.2013.01.001","article-title":"Bisphosphonate therapy and atypical fractures","volume":"44","author":"Saleh","year":"2013","journal-title":"The Orthopedic Clinics of North America"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/8756-3282(95)00448-3","article-title":"Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy","volume":"18","author":"Sauty","year":"1996","journal-title":"Bone"},{"issue":"9","key":"10.1002\/14651858.CD002010.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1164\/rccm.200606-776OC","article-title":"Low bone mineral density in young children with cystic fibrosis","volume":"175","author":"Sermet-Gaudelus","year":"2007","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","article-title":"European cystic fibrosis bone mineralisation guidelines","volume":"10 Suppl 2","author":"Sermet-Gaudelus","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcf.2009.11.007","article-title":"Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis","volume":"9","author":"Shead","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1479-5876-11-19","article-title":"TNF gene polymorphisms in cystic fibrosis patients: contribution to the disease progression","volume":"11","author":"Shmarina","year":"2013","journal-title":"Journal of Translational Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002010.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"e80098","DOI":"10.1371\/journal.pone.0080098","article-title":"Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease","volume":"8","author":"Stalvey","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1002\/14651858.CD002010.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.med.0000436191.87727.ec","article-title":"Cystic fibrosis-related bone disease: insights into a growing problem","volume":"20","author":"Stalvey","year":"2013","journal-title":"Current Opinion in Endocrinology, Diabetes and Obesity"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.1997.00586.x","article-title":"Suppression of human monocyte tumour necrosis factor-alpha release by glucocorticoid therapy: relationship to systemic monocytopaenia and cortisol suppression","volume":"43","author":"Steer","year":"1997","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD002010.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"125705","DOI":"10.1155\/2013\/125705","article-title":"The role of inflammatory cytokines, the RANKL\/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis","volume":"2013","author":"Weitzmann","year":"2013","journal-title":"Scientifica"},{"issue":"1","key":"10.1002\/14651858.CD002010.pub4-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004523.pub3","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002010.pub4-BIB0081|cit81","volume-title":"Cystic Fibrosis in Adults","author":"Yankaskas","year":"1999"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub4-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004523.pub2","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","author":"Brenckmann","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub4-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002010.pub2","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","author":"Conwell","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002010.pub4-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002010.pub3","article-title":"Bisphosphonates for osteoporosis in people with cystic fibrosis","author":"Conwell","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd002010.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002010.pub4\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T23:07:41Z","timestamp":1648595261000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002010.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,13]]},"references-count":84,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002010.pub4","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD002010.pub5","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,13]]}}}